Literature DB >> 15613909

Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.

Jason A Zell1, Eugene J Yoon, S-H Ignatius Ou, John C Hoefs, Jae C Chang.   

Abstract

A patient with stage IV non-Hodgkin's lymphoma and chronic hepatitis who was treated with chemotherapy and rituximab developed fatal reactivation of hepatitis B. High viral load titers of hepatitis B DNA were demonstrated. DNA sequencing analysis revealed the presence of the precore mutant strain. Hepatitis B reactivation in patients receiving rituxmab-based chemotherapy is reviewed and the role of precore mutant virus strains resulting in fatal complications is discussed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15613909     DOI： 10.1097/00001813-200501000-00012

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN： 0959-4973            Impact factor:   2.248


  4 in total

1.  Hepatitis C Virus-related Mixed Cryoglobulinemia: Pathogenesis, Clinica Manifestations, and New Therapies.

Authors:  Neal J Schamberg; Gerond V Lake-Bakaar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-09

2.  Screening for hepatitis B in patients with lymphoma.

Authors:  Jonathan Ramirez; Anupama Thadareddy Duddempudi; Moazzam M Sana; Syed S Hasan; Mario de Los Santos; Juhee Song; Ying Fang-Hollingsworth; Sandeep S Gupta; Dawn M Sears
Journal:  Proc (Bayl Univ Med Cent)       Date:  2015-10

3.  An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening.

Authors:  Christopher Leung; Edward Tsoi; Gareth Burns; William Sievert
Journal:  Oncologist       Date:  2011-04-04

Review 4.  Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

Authors:  Masaru Kato; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2015-11-16       Impact factor: 2.631
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.